| Aug to Nov 2028Quarter disclosed | TAK-330 | TAK | Topline readout | Coagulation Disorder | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2028Quarter disclosed | fazirsiran (TAK-999) | TAK | Topline readout | Alpha1-Antitrypsin Deficiency | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | fazirsiran (TAK-999) | TAK | Primary completion | Alpha1-Antitrypsin Deficiency | Scheduled | ClinicalTrials.gov |
| August 2028Month disclosed | TAK-330 | TAK | Primary completion | Coagulation Disorder | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | elritercept (KER-050) | TAK | Topline readout | Myelodysplastic Syndromes | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | mezagitamab (TAK-079) | TAK | Topline readout | Kidney Disease | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2028Quarter disclosed | igi, 10% (TAK-339) | TAK | Topline readout | Multiple Myeloma; Secondary Immunodeficiency | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | mezagitamab (TAK-079) | TAK | Primary completion | Kidney Disease | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | igi, 10% (TAK-339) | TAK | Primary completion | Multiple Myeloma; Secondary Immunodeficiency | Scheduled | ClinicalTrials.gov |
| September 2028Month disclosed | elritercept (KER-050) | TAK | Primary completion | Myelodysplastic Syndromes | Scheduled | ClinicalTrials.gov |
| November 2028Month disclosed | TAK-928 | TAK | Primary completion | IO Resistant Squamous and Nonsquamous NSCLC | Scheduled | ClinicalTrials.gov |
| Nov 2028 to Feb 2029Quarter disclosed | TAK-928 | TAK | Topline readout | IO Resistant Squamous and Nonsquamous NSCLC | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | fazirsiran (TAK-999) | TAK | Topline readout | Alpha1-Antitrypsin Deficiency | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | idursulfase-it | TAK | Primary completion | Hunter Syndrome | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | idursulfase-it | TAK | Topline readout | Hunter Syndrome | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2029Quarter disclosed | mezagitamab (TAK-079) | TAK | Topline readout | Antibody-Mediated Rejection (AMR) | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | mezagitamab (TAK-079) | TAK | Primary completion | Antibody-Mediated Rejection (AMR) | Scheduled | ClinicalTrials.gov |
| January 2029Month disclosed | fazirsiran (TAK-999) | TAK | Primary completion | Alpha1-Antitrypsin Deficiency | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2029Quarter disclosed | elritercept (KER-050) | TAK | Topline readout | Myelodysplastic Syndrome; Anemia | Scheduled | ClinicalTrials.gov |
| April 2029Month disclosed | elritercept (KER-050) | TAK | Primary completion | Myelodysplastic Syndrome; Anemia | Scheduled | ClinicalTrials.gov |
| Jul to Oct 2029Quarter disclosed | mezagitamab (TAK-079) | TAK | Topline readout | Immune Thrombocytopenic Purpura (ITP) | Scheduled | ClinicalTrials.gov |
| July 2029Month disclosed | mezagitamab (TAK-079) | TAK | Primary completion | Immune Thrombocytopenic Purpura (ITP) | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2029Quarter disclosed | TAK-279 | TAK | Topline readout | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| August 2029Month disclosed | TAK-279 | TAK | Primary completion | Plaque Psoriasis | Scheduled | ClinicalTrials.gov |
| Sep to Dec 2029Quarter disclosed | Trintellix (vortioxetine hydrobromide) | TAK | Topline readout | Major Depressive Disorder | Scheduled | ClinicalTrials.gov |
| September 2029Month disclosed | Trintellix (vortioxetine hydrobromide) | TAK | Primary completion | Major Depressive Disorder | Scheduled | ClinicalTrials.gov |
| Oct 2029 to Jan 2030Quarter disclosed | elritercept (KER-050) | TAK | Topline readout | Myelodysplastic Syndromes; Cytopenia | Scheduled | ClinicalTrials.gov |
| October 2029Month disclosed | elritercept (KER-050) | TAK | Primary completion | Myelodysplastic Syndromes; Cytopenia | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | zasocitinib (TAK-279) | TAK | Topline readout | Crohn's Disease; Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | zasocitinib (TAK-279) | TAK | Topline readout | Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| Dec 2029 to Mar 2030Quarter disclosed | elritercept (KER-050) | TAK | Topline readout | Myelofibrosis; Anemia | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | elritercept (KER-050) | TAK | Primary completion | Myelofibrosis; Anemia | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | zasocitinib (TAK-279) | TAK | Primary completion | Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| December 2029Month disclosed | zasocitinib (TAK-279) | TAK | Primary completion | Crohn's Disease; Ulcerative Colitis | Scheduled | ClinicalTrials.gov |
| Jan to Apr 2030Quarter disclosed | Entyvio® (vedolizumab) | TAK | Topline readout | Pouchitis | Scheduled | ClinicalTrials.gov |
| January 2030Month disclosed | Entyvio® (vedolizumab) | TAK | Primary completion | Pouchitis | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | vedolizumab iv (MLN0002) | TAK | Topline readout | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Mar to Jun 2030Quarter disclosed | tdv (TAK-003) | TAK | Topline readout | Dengue Fever | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | tdv (TAK-003) | TAK | Primary completion | Dengue Fever | Scheduled | ClinicalTrials.gov |
| March 2030Month disclosed | vedolizumab iv (MLN0002) | TAK | Primary completion | Crohn's Disease | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2030Quarter disclosed | vonicog alfa (TAK-577) | TAK | Topline readout | Von Willebrand Disease (VWD) | Scheduled | ClinicalTrials.gov |
| Apr to Jul 2030Quarter disclosed | zasocitinib (TAK-279) | TAK | Topline readout | Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| April 2030Month disclosed | vonicog alfa (TAK-577) | TAK | Primary completion | Von Willebrand Disease (VWD) | Scheduled | ClinicalTrials.gov |
| April 2030Month disclosed | zasocitinib (TAK-279) | TAK | Primary completion | Psoriatic Arthritis | Scheduled | ClinicalTrials.gov |
| Aug to Nov 2030Quarter disclosed | vedolizumab sc (MLN0002) | TAK | Topline readout | Ulcerative Colitis; Crohn's Disease | Scheduled | ClinicalTrials.gov |
| August 2030Month disclosed | vedolizumab sc (MLN0002) | TAK | Primary completion | Ulcerative Colitis; Crohn's Disease | Scheduled | ClinicalTrials.gov |